目的 探讨化滞柔肝颗粒联合硫普罗宁片治疗非酒精性脂肪肝的临床疗效。方法 选取2016年6月—2018年6月在青岛市第六人民医院进行治疗的100例非酒精性脂肪肝患者作为研究对象，根据用药的不同将患者分为对照组（50例）和治疗组（50例）。对照组患者口服硫普罗宁片，2片/次，3次/d；治疗组患者在对照组治疗的基础上口服化滞柔肝颗粒，1袋/次，3次/d。两组均治疗8周。观察两组患者的临床疗效，同时比较两组治疗前后的血脂水平、肝功能指标和血清学指标。结果 治疗后，对照组总有效率为82.00%，显著低于治疗组的96.00%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）水平均明显降低，高密度脂蛋白胆固醇（HDL-C）水平显著增高（P<0.05）；治疗后，治疗组血脂水平显著优于对照组（P<0.05）。治疗后，两组丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）和γ-谷氨酰转肽酶（γ-GT）水平均明显降低（P<0.05）；治疗后，治疗组肝功能指标显著低于对照组（P<0.05）。治疗后，两组瘦素（LEP）、摄食抑制因子-1（NSF-1）、成纤维细胞生长因子-21（FGF-21）、硫氧还蛋白相互作用蛋白（TXNIP）、低氧诱导因子-1α（HIF-1α）水平均显著降低（P<0.05）；治疗后，治疗组血清学指标显著低于对照组（P<0.05）。结论 化滞柔肝颗粒联合硫普罗宁片治疗非酒精性脂肪肝疗效确切，可改善患者肝功能，降低血脂和血清因子水平，具有一定的临床应用价值。

Objective To investigate the clinical efficacy of Huazhi Rougan Granules combined with Tiopronin Tablets in treatment of non-alcoholic fatty liver disease. Methods Patients (100 cases) with non-alcoholic fatty liver disease in the Qingdao No.6 People's Hospital from June 2016 to June 2018 were divided into the control group (50 cases) and the treatment group (50 cases) according to the medication. Patients in the control group were po administered with Tiopronin Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Huazhi Rougan Granules on the basis of control group, 1 bag/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the blood lipid levels, liver function, and serological indicators in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 82.00%, which was significantly lower than 96.00% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, TC, TG, and LDL-C levels in two groups were significantly decreased, but HDL-C levels were increased (P< 0.05). After treatment, the blood lipid levels in the treatment group were significantly better than those in the control group (P< 0.05). After treatment, the levels of ALT, AST, and γ-GT in two groups were significantly decreased (P< 0.05). After treatment, liver function indexes in the treatment group were significantly lower than those in the control group (P< 0.05). After treatment, the LEP, NSF-1, FGF-21, TXNIP, and HIF-1α levels in two groups were significantly decreased (P< 0.05). After treatment, the levels of serological indicators in the treatment group were significantly lower than those in the control group (P< 0.05). Conclusion Huazhi Rougan Granules combined with Tiopronin Tablets has clinical curative effect in treatment of non-alcoholic fatty liver disease, can effectively improve patients' liver function, can reduce blood lipid and serum factor levels, which has a certain clinical application value.